News und Analysen
Novocure Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update
Novocure (NASDAQ: NVCR) today reported financial results for the fourth quarter and full year ended December 31, 2022. Novocure is a global oncology company working to extend survival in some of
Allyson J. Ocean, M.D., Joins Novocure Board of Directors
Novocure (NASDAQ: NVCR) today announced that Allyson J. Ocean, M.D., has been elected to Novocure’s Board of Directors.
“We are honored to welcome Dr. Ocean to our board of directors,” said
Premier Inc. Acquires 100 Top Hospitals® Program
Premier Inc. (NASDAQ: PINC) acquired the 100 Top Hospitals® program from Merative (formerly IBM Watson Health). The program will be integrated within PINC AI™, Premier’s technology and services
Xencor to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 23, 2023
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that it
Novocure Announces Last Patient Enrolled in Pivotal PANOVA-3 Study of Tumor Treating Fields in Pancreatic Cancer
Novocure (NASDAQ: NVCR) today announced that the final patient has been enrolled in the pivotal PANOVA-3 study evaluating the efficacy of Tumor Treating Fields (TTFields) together with
Premier’s PINC AI™ Receives 2023 Best in KLAS Award for Value-Based Care Consulting
PINC AI™, the technology and services platform of Premier Inc. (NASDAQ: PINC), a leading healthcare improvement and technology company, has been awarded the 2023 Best in KLAS designation for
Acadia Healthcare Announces Date for Fourth Quarter and Year-End 2022 Earnings Release
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it will release its fourth quarter and year-end 2022 results on Monday, February 27, 2023, after the close of the market. Acadia
Xencor to Present at the SVB Securities Global Biopharma Conference
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that
Premier, Inc. Reports Fiscal-Year 2023 Second-Quarter Results
Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today reported financial results for the fiscal year 2023 second quarter ended December 31, 2022. The
Premier, Inc. Declares Quarterly Cash Dividend
Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today announced that its Board of Directors declared a cash dividend of $0.21 per share of Class A common
Novocure Announces Organizational Changes to Prepare for Future Growth
Novocure (NASDAQ: NVCR) today announced organizational changes to prepare for future growth, effective Jan. 17.
Pritesh Shah, Novocure’s Chief Commercial Officer, will transition into a new
Xencor Highlights 2023 Corporate Priorities and Provides Portfolio Updates
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced 2023
Novocure Announces Preliminary Full Year and Fourth Quarter 2022 Net Revenues and Provides Company Update
Novocure (NASDAQ: NVCR) today reported preliminary unaudited financial results and operational updates for the quarter and full year ended December 31, 2022. Novocure is a global oncology company
Novocure Announces Pivotal LUNAR Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint
Novocure (NASDAQ: NVCR) today announced the LUNAR study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in overall survival over standard
Xencor to Present at the 41st Annual J.P. Morgan Healthcare Conference
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that
Acadia Healthcare to Present at the 41st Annual J.P. Morgan Healthcare Conference
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that the Company will present at the 41st Annual J.P. Morgan Healthcare Conference, January 9-12, 2023, at The Westin St. Francis, San
Premier, Inc. to Report Fiscal 2023 Second-Quarter Results and Host Conference Call on February 7, 2023
Premier, Inc. (NASDAQ: PINC) today announced that it will release financial results for its fiscal 2023 second quarter on Tuesday, February 7, at approximately 6:30 a.m. EST. The company will also
Premier Inc. to Participate in 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023
Premier Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today announced that members of its management team will participate in the 41st Annual J.P. Morgan
Novocure to Participate in 41st Annual J.P. Morgan Healthcare Conference
Novocure (NASDAQ: NVCR) announced today it will participate in the 41st Annual J. P. Morgan Healthcare Conference on January 10-11, 2023. William Doyle, Novocure’s Executive Chairman, will speak on
Xencor Presents Data from Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin Lymphoma at the American Society of Hematology Annual Meeting
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced
Acadia Healthcare Provides Business Outlook Ahead of Investor Day
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) will host its first Investor Day beginning at approximately 9:00 a.m. Eastern Time today, Wednesday, December 7, 2022, in New York City.
During the
Maple Heights Behavioral Health Hosts Ceremony to Celebrate Grand Opening
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced its newest operating joint venture hospital, Maple Heights Behavioral Health, located in Fort Wayne, Indiana, and held a ribbon-tying
Novocure’s Optune® Approved in Canada for the Treatment of Newly Diagnosed and Recurrent Glioblastoma
Novocure (NASDAQ: NVCR) today announced that Health Canada has approved Optune® for the treatment of newly diagnosed and recurrent glioblastoma (GBM). GBM is the most common and one of the most
Premier, Inc. to Participate in Piper Sandler 34th Annual Healthcare Conference on November 30, 2022
Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, announced today that members of its management team are scheduled to participate in a fireside chat at the
Novocure to Participate in 34th Annual Piper Sandler Healthcare Conference
Novocure (NASDAQ: NVCR) announced today it will participate in the 34th Annual Piper Sandler Healthcare Conference on December 1, 2022. William Doyle, Novocure’s Executive Chairman, and Ashley